2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
217
Recurrence
26
Neoplasms, Plasma Cell
15
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Myeloid, Acute
9
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Smoldering Multiple Myeloma
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Hematologic Neoplasms
4
Plasmacytoma
3
Paraproteinemias
3
Myelodysplastic Syndromes
3
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Diseases
3
Carcinoma, Non-Small-Cell Lung
3
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Plasmablastic Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
delta 24-sterol reductase
1
decitabine and cedazuridine drug combination
1
daratumumab
1
apalutamide
1
Validation Studies as Topic
1
Trastuzumab
1
Tape Recording
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Pilot Projects
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Focus Groups
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Preference
×
daratumumab
×
Clear all
NCT05284591
2024-10-01
MYLENE
iOMEDICO AG
Completed
96 enrolled